Subscribe to this collection to receive daily e-mail notification of new additions

	Title	Author(s)	Issue Date	Views
	The trends in lung cancer prevalence, incidence, and survival in Hong Kong over the past two decades (2002–2021): a population-based study Journal:The Lancet Regional Health - Western Pacific	Au, Philip CMLee, Anne WMLee, Victor HFWong, Ian CKHui, Rina YMCheung, Ching-Lung	16-Feb-2024
	Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study Journal:Lung Cancer	Subramanian, JLeighl, NBChoi, YLChou, TYGregg, JHui, RMarchetti, ASilvey, MMakin, RGillespie-Akar, LTaylor, AKahangire, DABailey, TChau, MNavani, N	15-Nov-2021
	Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study Journal:Thoracic Cancer	Boys, EmmaGao, BoHui, Rinada Silva, InêsHau, EricGee, HarrietNagrial, Adnan	10-Jan-2023
	Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC Journal:JTO Clinical and Research Reports	Garassino, MCGadgeel, SNovello, SHalmos, BFelip, ESperanza, GHui, RGaron, EBHorinouchi, HSugawara, SRodriguez-Abreu, DReck, MCristescu, RAurora-Garg, DLoboda, ALunceford, JKobie, JAyers, MPiperdi, BPietanza, MCPaz-Ares, L	8-Nov-2021
	Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study Journal:Journal of Clinical Oncology	Garassino, MCGadgeel, SSperanza, GFelip, EEsteban, EDómine, MHochmair, MJPowell, SFBischoff, HGPeled, NGrossi, FJennens, RRReck, MHui, RGaron, EBKurata, TGray, JESchwarzenberger, PJensen, EPietanza, MCRodríguez-Abreu, D	10-Apr-2023
	Symptomatic Pneumonitis with Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer Journal:JTO Clinical and Research Reports	Vansteenkiste, Johan FNaidoo, JarushkaFaivre–Finn, CorinneÖzgüroğlu, MustafaVillegas, AugustoDaniel, DaveyMurakami, ShujiHui, RinaLee, Ki HyeongCho, Byoung ChulKubota, KaoruBroadhurst, HelenWadsworth, CatherineNewton, MichaelThiyagarajah, PirunthaAntonia, Scott J	17-Jan-2024
	Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies Journal:European Journal of Cancer	Shahnam, AdelHitchen, NadiaNindra, UditManoharan, SathyaDesai, JayeshTran, BenSolomon, BenjaminLuen, Stephen JHui, RinaHopkins, Ashley MSorich, Michael J	18-Dec-2023
	Event-Free Survival by Residual Cancer Burden with Pembrolizumab in Early-Stage TNBC: Exploratory Analysis from KEYNOTE-522 Journal:Annals of Oncology	Pusztai, LDenkert, CO’Shaughnessy, JCortes, JDent, RMcArthur, HKummel, SBergh, JPark, YHHui, RHarbeck, NTakahashi, MUntch, MFasching, PACardoso, FZhu, YPan, WTryfonidis, KSchmid, P	16-Feb-2024
	Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826) Journal:European Journal of Cancer	Hamilton, EMeisel, JAlemany, CVirginia, BLin, NWesolowski, RMathauda-Sahota, GMakower, DLawrence, JFaltaos, DMitri, ZSabanathan, DClark, DPluard, THui, RMcCarthy, NPatel, M	1-Oct-2022
	Asbestos-related lung cancer: Clinical characteristics and survival outcomes in an Australian cohort seeking workers compensation Journal:Asia-Pacific Journal of Clinical Oncology	Hyland, Rebecca A.Chrzanowska, AgataHannaford-Turner, KirstyDavis, AlexanderKe, HelenBradbury, LaurenNagrial, AdnanMcCaughan, BrianHui, Rinavan Zandwijk, NicoTakahashi, KenKao, Steven C.	2022
	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer Journal:New England Journal of Medicine	Schmid, PeterCortes, JavierDent, RebeccaPusztai, LajosMcArthur, HeatherKümmel, SherkoBergh, JonasDenkert, CarstenPark, Yeon HeeHui, RinaHarbeck, NadiaTakahashi, MasatoUntch, MichaelFasching, Peter A.Cardoso, FatimaAndersen, JayPatt, DebraDanso, MichaelFerreira, MartaMouret-Reynier, Marie AngeIm, Seock AhAhn, Jin HeeGion, MariaBaron-Hay, SallyBoileau, Jean FrançoisDing, YuTryfonidis, KonstantinosAktan, GurselKarantza, VassilikiO'Shaughnessy, Joyce	2022
	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials Journal:JNCI Cancer Spectrum	Man, JohnathanMillican, JaredMulvey, ArthurGebski, ValHui, Rina	2021
	Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing Journal:Breast Cancer Research and Treatment	Dinh, PhuongGraham, J. DinnyElder, Elisabeth N.Kabir, MasruraDoan, Tram B.French, JamesMeybodi, FaridHui, RinaWilcken, Nicholas R.Harnett, Paul R.Hsu, JeremyStuart, Kirsty E.Wang, TimAhern, VerityBrennan, MeaganFox, Stephen B.Dear, Rachel F.Lim, ElgeneWhite, MichelleMann, G. BrucePathmanathan, Nirmala	2022
	Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 Journal:Annals of Oncology	Rodríguez-Abreu, D.Powell, S. F.Hochmair, M. J.Gadgeel, S.Esteban, E.Felip, E.Speranza, G.De Angelis, F.Dómine, M.Cheng, S. Y.Bischoff, H. G.Peled, N.Reck, M.Hui, R.Garon, E. B.Boyer, M.Kurata, T.Yang, J.Pietanza, M. C.Souza, F.Garassino, M. C.	2021
	Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ‡ 50% Journal:Journal of Clinical Oncology	Reck, MartinRodríguez-Abreu, DelvysRobinson, Andrew G.Hui, RinaCsöszi, TiborFülöp, AndreaGottfried, MayaPeled, NirTafreshi, AliCuffe, SineadO’Brien, MaryRao, SumanHotta, KatsuyukiLeal, Ticiana A.Riess, Jonathan W.Jensen, ErinZhao, BinPietanza, M. CatherineBrahmer, Julie R.	2021
	Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC) Journal:Clinical Lung Cancer	Socinski, Mark A.Özgüroğlu, MustafaVillegas, AugustoDaniel, DaveyVicente, DavidMurakami, ShujiHui, RinaGray, Jhanelle E.Park, KeunchilVincent, MarkMann, HelenNewton, MichaelDennis, Phillip A.Antonia, Scott J.	2021
	Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time? Journal:Journal for ImmunoTherapy of Cancer	Ahern, ElizabethSolomon, Ben J.Hui, RinaPavlakis, NickO'Byrne, KenHughes, Brett G.M.	2021
	Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors Journal:Lung Cancer	Liu, JiaItchins, MalindaNagrial, AdnanCooper, Wendy A.De Silva, MadhawaBarnet, MeganVarikatt, WinnySivasubramaniam, VanathiDavis, AlexanderGill, Anthony J.Blinman, PrunellaLee, KennethHui, RinaGao, BoPavlakis, NickClarke, StephenLee, JennyBoyer, MichaelKao, Steven	2021
	CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care Journal:Asia-Pacific Journal of Clinical Oncology	Hui, Rinade Boer, RichardLim, ElgeneYeo, BelindaLynch, Jodi	2021
	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) Journal:Lung Cancer	Faivre-Finn, CorinneSpigel, David R.Senan, SureshLanger, CoreyPerez, Bradford A.Özgüroğlu, MustafaDaniel, DaveyVillegas, AugustoVicente, DavidHui, RinaMurakami, ShujiPaz-Ares, LuisBroadhurst, HelenWadsworth, CatherineDennis, Phillip A.Antonia, Scott J.	2021